#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Paraneoplastic neurological syndrome Osteomyelitis Pyoderma gangrenosum Gastric cancer Systemic candida Progressive multifocal leukoencephalopathy Breast cancer Malignant glioma Necrotising enterocolitis neonatal Eosinophilic oesophagitis Autoimmune myositis Fallopian tube cancer Congenital absence of bile ducts Ewing's sarcoma metastatic Skin angiosarcoma More trials…

    Learn about Rare Diseases

    Synovial sarcoma metastatic – Basic Information Cerebral arteriovenous malformation haemorrhagic – Diagnostics Adrenocortical carcinoma – Treatment Rett syndrome Prolymphocytic leukaemia – Treatment Mast cell activation syndrome – Treatment Chondrosarcoma Behcet’s syndrome – Trials in Disease Myelodysplastic syndrome with excess blasts – Diagnostics Netherton’s syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Iohexol Isosorbide Dinitrate Azd5004 MAGNESIUM CARBONATE HEAVY Siremadlin Anb032 Propofol Quercetin Ferrous Sulfate Ro7269162 Vorinostat Psilocybine IBANDRONIC ACID Oxymetazoline Hydrochloride Cipaglucosidase Alfa Cldn6 Car-T HYPOCHLOROUS ACID Tryptophan ARI0008 Izokibep More therapies…

    Learn about Your Condition

    Thyroidectomy Uterine leiomyosarcoma Heparin resistance Lipid metabolism disorder Cervix carcinoma Partial seizures Prostatitis Escherichia coli Synovitis Dyslipidaemia Malignant mast cell neoplasm Noninfective chorioretinitis Encephalopathy neonatal Post procedural oedema Congenital myopathy Bacterial infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Bladder cancer

  • Study on the Effectiveness of Gemcitabine Hydrochloride for Patients with Low Grade Bladder Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Gemcitabine Hydrochloride
    Austria

  • Study of Atezolizumab After Chemo-radiotherapy for Patients with Muscle-invasive Bladder Cancer Not Eligible for Radical Surgery

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Atezolizumab
    France

  • Study of AZD9574 and Temozolomide for Patients with Advanced Solid Tumors, Including Breast, Ovarian, Pancreatic, and Prostate Cancers

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Metastases to biliary tract
    • Metastases to central nervous system
    • Metastatic glioma
    Investigated Drugs:
    • 6-Fluoro-5-[4-[(5-Fluoro-2-Methyl-3-Oxo-4H-Quinoxalin-6-Yl)Methyl]Piperazin-1-Yl]-N-Methylpyridine-2-Carboxamide
    • [11C]Az14193391
    • Trastuzumab Deruxtecan
    Spain Sweden

  • Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Enfortumab Vedotin
    • Pembrolizumab
    France Germany Italy Poland Spain

  • Study of Sacituzumab Govitecan and Zimberelimab for Muscle-Invasive Bladder Cancer in Patients Unable to Take Cisplatin or Unwilling to Have Surgery

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Zimberelimab
    Italy

  • Study on the Effectiveness of Hexaminolevulinate in Bladder Cancer Surgery for Patients with Non-Muscle Invasive Bladder Cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Hexaminolevulinate
    Italy
Previous Page
1 2 3 4 5 … 9
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!